Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
Why Is Natera, Inc. (NTRA) Stock Up +2.39% Today?

Why Is Natera, Inc. (NTRA) Stock Up +2.39% Today?

Key Takeaways

  • Natera, Inc. (NTRA) shares rose 2.39% to $296.43 in midday trading Thursday, up $6.93 from the prior close of $289.50.
  • No company-issued press release, SEC filing, or new analyst rating was published Thursday, so the advance is best characterized as a continuation of the post-selloff rebound rather than a news-driven move.
  • Momentum was reinforced by relative strength in molecular diagnostics peers, with Guardant Health and Veracyte both trading higher while the broader tape fell.
  • The gain came against a weak market backdrop: the S&P 500 and Nasdaq-100 were each down roughly 0.9%, and the health care sector ETF slipped about 1.7%.
  • Even after Thursday's rally, the stock sits about 32% below its Oct. 29 closing high of $436.00 and remains well under its 50-day moving average.
  • What traders are watching next: whether the $277–$290 zone holds as support, and whether pending Medicare MolDx coverage decisions and the Japan launch arrive before fourth-quarter results in late February.
  • News Significance Score: 10/100 — no fresh verified catalyst, and a move barely larger than this stock's routine daily swing.
  • Readers can explore detailed Price Targets, Earnings history, and Forecast pages for deeper research on the name.
  • For systematic, rules-based exposure to momentum and trend signals, explore Tickeron's Trending AI Robots.

Opening Summary

Natera, Inc. (NTRA) is an Austin, Texas–based molecular diagnostics company whose cell-free DNA platform powers Signatera, a personalized blood test that detects residual cancer DNA after treatment, along with Panorama prenatal screening and Prospera organ-transplant rejection monitoring. In Thursday's session, the stock traded at $296.43, up 2.39% from the previous close of $289.50, confirming an upward move. No verified company-specific catalyst was identified for the advance; the gain instead reflects buyers stepping into a name that had fallen more than 30% from its late-October peak, with support from relative strength in diagnostics peers.

No Verified News or Fundamental Catalyst Found

No verified news or fundamental catalyst found in Thursday's flow. There was no earnings report, guidance update, regulatory decision, financing, or new sell-side action tied to the session. The most likely explanation is technical: a rebound attempt in an oversold large cap after a sharp post-earnings repricing. NTRA fell 14.59% on Nov. 6, the session after third-quarter results, and another 9.59% on Nov. 16, a cumulative decline of more than 20% in eight sessions. Shares have now stabilized across three consecutive sessions, closing at $287.47, then $289.50, and trading higher again Thursday. That pattern is consistent with dip-buying and short-term position resetting rather than a reassessment of fundamentals.

Digesting the CRUSH Rule and the Leadership Handoff

The two overhangs that drove the November decline are both being re-examined by investors. First, the Centers for Medicare & Medicaid Services published its proposed CRUSH anti-fraud rule on Nov. 16, and the 545-page proposal contains no dedicated laboratory or molecular diagnostics provisions — a relief for a group that had feared new registration requirements for proprietary tests. Second, the company's immediate CEO transition, with Solomon Moshkevich succeeding Steve Chapman, has been repeatedly framed by management as continuity; the CFO has publicly defended the abrupt handoff and reiterated the $6 billion 2029 revenue target. Neither item is new Thursday, but both reduce the probability of further forced selling.

Diagnostics Peers Outperform a Weak Tape

The move was idiosyncratic rather than sector-wide. Guardant Health rose about 2.9% and Veracyte gained roughly 1.8%, while GeneDx and Illumina traded lower. The divergence suggests money is rotating selectively toward precision-diagnostics names with differentiated oncology franchises rather than buying the group indiscriminately — a pattern that favors NTRA given Signatera's position as the most widely adopted molecular residual disease test in the United States.

Market Context and Trading Activity

Volume was unremarkable: roughly 630,000 shares had changed hands by midday against an average daily volume near 1.7 million, implying a pace broadly in line with normal activity. That lack of volume confirmation argues against reading Thursday's gain as institutional accumulation. The stock opened higher near $294.75, reached an intraday high of $307.19, and then pared the advance, which itself signals that sellers remain active above $300. The move ran directly against the broader market, with the S&P 500 and Nasdaq-100 each down about 0.9% and the health care sector ETF off roughly 1.7%. Technically, the shares remain well below their 50-day moving average and roughly 32% under the 52-week closing high of $436.00, with the mid-$270s — the low of the Nov. 16–18 sessions — emerging as the nearest support level.

News Significance Score

The score runs from 0, meaning no meaningful news and a move entirely normal for the stock, to 100, meaning transformative news and an extreme, rare price move. This session earns a 10 out of 100. There was no verified company news at all, only the ongoing digestion of announcements already made earlier in November, which is weak by any materiality standard for a company with a market capitalization above $40 billion. The price move was equally unremarkable: at 2.39%, it was just over one times the stock's average absolute daily change of 2.33% across the past 60 sessions, and moves of that size or larger occurred 23 times in that window. Two modest components combine into a low score.

What Comes Next for NTRA

Fourth-quarter and full-year 2026 results are expected in late February 2027, and investors will focus on two metrics: clinical Signatera unit growth, which reached roughly 316,000 in the third quarter, and the operating margin, which narrowed sharply on a trailing basis but still sits in negative territory. Management has guided full-year revenue to $3.005–$3.035 billion and targets $6 billion by 2029. Near-term catalysts include nine to ten pending MolDx submissions for additional cancer types, the Signatera launch in Japan, broader adoption of the Signatera Genome assay, and a 2027 readout from the 30,000-patient FIND colorectal screening study. Risks include gross-margin dilution from newer products, competitive entry into tumor-informed MRD testing, reimbursement timing, and the execution risk inherent in a first-year CEO. Valuation near 14 times trailing sales leaves little room for disappointment.

Trending AI Robots

Tickeron operates hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions earn a place in the curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the page functions as a live screen of what is currently working rather than a static list. Investors looking to pair fundamental research with systematic signals can review the current leaders.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: NTRA

NTRA in downward trend: 10-day moving average moved below 50-day moving average on November 10, 2026

The 10-day moving average for NTRA crossed bearishly below the 50-day moving average on November 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 77%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTRA as a result. In 66 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.

The Moving Average Convergence Divergence Histogram (MACD) for NTRA turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 30 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 61%.

NTRA moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.

The Aroon Indicator for NTRA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +3.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRA advanced for three days, in 246 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

NTRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (24.585) is normal, around the industry mean (67.298). NTRA's P/E Ratio (-230.126) is considerably lower than the industry average of (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (17.857) is also within normal values, averaging (9.775).

The Tickeron Profit vs. Risk Rating rating for this company is 35 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock slightly better than average.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating fairly steady price growth. NTRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are IQVIA Holdings (NYSE:IQV), Illumina (NASDAQ:ILMN), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 20.94B. The market cap for tickers in the group ranges from 27 to 4.39T. MKYSF holds the highest valuation in this group at 4.39T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was -8%. For the same Industry, the average monthly price growth was -13%, and the average quarterly price growth was 20%. VCYT experienced the highest price growth at 2%, while IMDX experienced the biggest fall at -33%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was 3%. For the same stocks of the Industry, the average monthly volume growth was 1% and the average quarterly volume growth was -30%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 52
Price Growth Rating: 51
SMR Rating: 78
Profit Risk Rating: 87
Seasonality Score: 26 (-100 ... +100)
AI Robots 7
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a genetic testing company which develops proprietary bioinformatics-based technology

Industry MedicalSpecialties

Industry
Biotechnology
Address
13011 McCallen Pass
Phone
+1 650 980-9190
Employees
6140
Web
https://www.natera.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.